TNF and psoriasis: TNF inhibitors were associated with a significant lower risk of cardiovascular events compared with topical treatment/phototherapy (RR, 0.58; 95% CI, 0.43 to 0.77) and methotrexate treatment (RR, 0.67; 95% CI, 0.52 to 0.88) in patients with psoriasis.